PMID- 28678332
OWN - NLM
STAT- MEDLINE
DCOM- 20180709
LR  - 20221207
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 21
IP  - 11
DP  - 2017 Jun
TI  - Effect of different blood glucose intervention plans on elderly people with type 
      2 diabetes mellitus combined with dementia.
PG  - 2702-2707
LID - 11426 [pii]
AB  - OBJECTIVE: We analyzed the effects of intensive and mitigatory blood glucose 
      control strategy on elderly people with type 2 diabetes mellitus (T2DM) combined 
      with Alzheimer disease (AD). PATIENTS AND METHODS: We enrolled 90 elderly 
      patients with T2DM combined with AD to participate in this study. They were 
      randomly divided into 3 groups: the control group, the strength group and the 
      mitigation group with 30 cases in each group. In the control group, patients were 
      only treated with diet and exercise while in the strength group patients were 
      treated with oral hypoglycemic medications, subcutaneous insulin infusion or 
      continuous infusion by micropump. Blood glucose level in the strength group 
      patients was stabilized within 1 month (pre-meal </= 7.0 mmol/L, 2 hours post-meal 
      glucose </= 12.0 mmol/L and glycosylated hemoglobin or HbA1c </= 7.0%). Personalized 
      treatment programs were adopted for the mitigation group and the objective was to 
      control the pre-meal blood glucose at </= 10.0 mmol/L (within 3 to 6 months) and 
      also to control 2 hours post-meal blood glucose at </= 20.0 mmol/L (within 3 to 6 
      months). We compared the occurrence rate of diabetic complications, occurrence 
      rate of new-onset dementia and progressive rate of dementia. RESULTS: Our results 
      showed that target glucose rate in the mitigation group was significantly higher 
      than that in the strength group. The occurrence rate of diabetic complications in 
      the mitigation group was significantly lower than that observed in the other two 
      groups. Occurrence rate of diabetic hyperosmolar coma was significantly higher in 
      the control group, the occurrence rate of hypoglycemia was meaningfully lower in 
      the strength group and the occurrence rate of new-onset target-organ injury was 
      considerably higher in the mitigation group. The occurrence rate of new-onset 
      dementia and progressive rate of dementia in mitigation group was significantly 
      lower than those in other two groups. Comparison between the control group and 
      the strength group did not reveal any statistical significance (p > 0.05). In the 
      meantime, the survival time in mitigation group was significantly longer. 
      CONCLUSIONS: Elderly patients with T2DM combined with AD may benefit more from 
      the moderate control of blood glucose and a proper increase of the target value.
FAU - Chen, Y
AU  - Chen Y
AD  - Department of Endocrinology, Fujian Institute of Endocrinology, Union Hospital of 
      Fujian Medical University Fuzhou, Fujian Province, China. huang_peiji1@163.com.
FAU - Wang, J
AU  - Wang J
FAU - Wang, L-J
AU  - Wang LJ
FAU - Lin, H
AU  - Lin H
FAU - Huang, P-J
AU  - Huang PJ
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
SB  - IM
MH  - Aged
MH  - Alzheimer Disease/blood/complications/*drug therapy
MH  - Blood Glucose/*analysis
MH  - China
MH  - Diabetes Mellitus, Type 2/blood/complications/*drug therapy
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemia/chemically induced
MH  - Hypoglycemic Agents/administration & dosage/*therapeutic use
MH  - Insulin/administration & dosage/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Postprandial Period
EDAT- 2017/07/06 06:00
MHDA- 2018/07/10 06:00
CRDT- 2017/07/06 06:00
PHST- 2017/07/06 06:00 [entrez]
PHST- 2017/07/06 06:00 [pubmed]
PHST- 2018/07/10 06:00 [medline]
AID - 11426 [pii]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2017 Jun;21(11):2702-2707.